Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.

Fasig JH, Dupont WD, LaFleur BJ, Olson SJ, Cates JM.

Neuropathol Appl Neurobiol. 2008 Feb;34(1):95-104. Epub 2007 Oct 31.

PMID:
17973908
2.

Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.

Akhavan-Sigari R, Abili M, Gaab MR, Rohde V, Zafar N, Emami P, Ostertag H.

Neurosurg Rev. 2015 Jan;38(1):89-98; discussion 98-9. doi: 10.1007/s10143-014-0579-x. Epub 2014 Oct 17.

PMID:
25323095
3.

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, Casali PG, Pierotti MA, Pilotti S.

Neuro Oncol. 2010 Aug;12(8):776-89. doi: 10.1093/neuonc/noq003. Epub 2010 Feb 17.

4.

Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.

de Castro CV, Guimaraes G, Aguiar S Jr, Lopes A, Baiocchi G, da Cunha IW, Campos AH, Soares FA, Begnami MD.

Hum Pathol. 2013 Sep;44(9):1747-55. doi: 10.1016/j.humpath.2012.11.024. Epub 2013 Apr 22.

PMID:
23618355
5.

The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.

Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TR, Bacsi K, Kindblom LG, Athanasou N, Amary MF, Hogendoorn PC, Tirabosco R, Flanagan AM.

J Pathol. 2011 Feb;223(3):336-46. doi: 10.1002/path.2818. Epub 2010 Dec 10.

PMID:
21171079
6.

Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.

Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A, Sasaki CT.

Arch Otolaryngol Head Neck Surg. 2005 Aug;131(8):707-11.

PMID:
16103303
7.

Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.

Tan PK, Wang J, Littler PL, Wong KK, Sweetnam TA, Keefe W, Nash NR, Reding EC, Piu F, Brann MR, Schiffer HH.

Mol Pharmacol. 2007 Dec;72(6):1440-6. Epub 2007 Aug 22.

8.

Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.

Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC, Flanagan AM.

Mod Pathol. 2009 Aug;22(8):996-1005. doi: 10.1038/modpathol.2009.63. Epub 2009 May 1.

9.

The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma.

Do SI, Jung WW, Kim HS, Park YK.

Int J Oncol. 2009 Mar;34(3):797-803.

PMID:
19212684
10.

Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.

Perrone F, Jocollè G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S.

Eur J Cancer. 2010 Oct;46(15):2837-48. doi: 10.1016/j.ejca.2010.06.130. Epub 2010 Aug 6.

PMID:
20692828
11.

Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.

Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Kelley MJ, Cates JM.

J Pathol. 2010 Apr;220(5):608-17. doi: 10.1002/path.2679.

PMID:
20140939
12.

Steroid hormone receptor and COX-2 expression in chordoma.

Fasig JH, Dupont WD, Olson SJ, Lafleur BJ, Cates JM.

Am J Clin Pathol. 2007 Sep;128(3):375-81.

PMID:
17709310
13.

Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.

Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, Gronchi A, Pastorino U, Pierotti MA, Pilotti S.

J Pathol. 2007 Jun;212(2):227-35.

PMID:
17471466
14.

Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.

Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, Merkelbach-Bruse S, Buettner R, Heukamp LC.

J Cancer Res Clin Oncol. 2009 May;135(5):723-30. doi: 10.1007/s00432-008-0509-9. Epub 2008 Nov 11.

PMID:
19002495
15.

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.

Abdeen A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, Kim M, Wang D, Moody K, Gorlick R.

Cancer. 2009 Nov 15;115(22):5243-50. doi: 10.1002/cncr.24562.

16.

EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.

Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A.

Mod Pathol. 2009 Oct;22(10):1328-40. doi: 10.1038/modpathol.2009.104. Epub 2009 Jul 31.

17.

Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value.

Hbibi AT, Lagorce C, Wind P, Spano JP, Des Guetz G, Milano G, Benamouzig R, Rixe O, Morere JF, Breau JL, Martin A, Fagard R.

Cancer Biomark. 2008;4(2):83-91.

PMID:
18503159
18.

A novel target for treatment of chordoma: signal transducers and activators of transcription 3.

Yang C, Schwab JH, Schoenfeld AJ, Hornicek FJ, Wood KB, Nielsen GP, Choy E, Mankin H, Duan Z.

Mol Cancer Ther. 2009 Sep;8(9):2597-605. doi: 10.1158/1535-7163.MCT-09-0504. Epub 2009 Sep 1.

19.

Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.

Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y.

Carcinogenesis. 2009 Jul;30(7):1097-105. doi: 10.1093/carcin/bgp097. Epub 2009 Apr 20.

PMID:
19380521
20.

Pulmonary vein stenosis: expression of receptor tyrosine kinases by lesional cells.

Riedlinger WF, Juraszek AL, Jenkins KJ, Nugent AW, Balasubramanian S, Calicchio ML, Kieran MW, Collins T.

Cardiovasc Pathol. 2006 Mar-Apr;15(2):91-9.

PMID:
16533697

Supplemental Content

Support Center